Navigation Links
Metastatic Bone Disease Patients Can Walk in Lazarus' Footsteps
Date:3/9/2009

"Miraculous" Effects, Pain Relief of Osteoplasty -- an Interventional Radiology Treatment -- Detailed for Those Suffering From Cancer Spread

SAN DIEGO, March 9 /PRNewswire-USNewswire/ -- Osteoplasty -- a highly effective minimally invasive procedure to treat the painful effects of metastatic bone disease by injecting bone cement to support weakened bones -- provides immediate and substantial pain relief, often presenting individuals who are suffering terribly with the miraculous so-called "Lazarus effect," according to researchers at the Society of Interventional Radiology's 34th Annual Scientific Meeting. Interventional radiologists often couple osteoplasty with heat or cold treatments to kill tumor nerves, if needed.

"The immediate good clinical results observed in our patients should encourage more widespread application of this palliative interventional radiology treatment," said Giovanni C. Anselmetti, M.D., interventional radiologist at the Institute for Cancer Research and Treatment in Turin, Italy. "A patient's quality of life can be severely affected when they have metastatic bone disease. Normal daily activities can become difficult when the metastases become painful, and many patients report that their sleep patterns change, appetite diminishes and the need to take pain relief medications increases," he noted. "Osteoplasty is not a first-line treatment. It is a highly effective minimally invasive procedure that provides pain relief for patients not responding to conventional pain medication treatments," he said. "Metastatic bone disease patients -- who have no other options, who are in pain, who have short life expectancies and who have dismal quality of life -- should be referred to interventional radiologists for osteoplasty treatment. Interventional radiologists can improve the quality of life for patients who have very large metastases and who are going to die because of their primary cancers," added Anselmetti.

Metastatic bone disease is a painful condition that can develop in conjunction with cancers of the breast, bladder, kidney, lung or other organs. It occurs when cancer cells at an original site metastasize or travel to the bone. These metastases can become widespread throughout the skeletal system. Some bone metastases become painful because the tumor eats away at the bone (ostelolysis), creating holes that make the bone thin and weak. As the bones are replaced with tumor, nerve endings in and around the bone send pain signals to the brain and the bone loses its functional strength. If left untreated, bone metastases can eventually cause the bone to fracture and seriously affect a patient's quality of life. Each year, about 100,000 cases of bone metastasis are reported in the United States.

In treating cancer patients with painful bone metastases, interventional radiologists may also use radiofrequency ablation (RFA) or cryoablation. These treatments use heat or cold to desensitize the bone by killing the nerve endings in the vicinity of the metastasis. Once the nerve endings are dead, interventional radiologists can perform osteoplasty. Osteoplasty involves the injection of semi-liquid bone cement (in this case, polymethyl-methacrylate or PMMA) into a bone lesion under constant and precise visual monitoring by CT or digital fluoroscopy imaging. The technique is similar to vertebroplasty, an interventional radiology treatment that has been used extensively in the spine to treat the pain of compression fractures.

In the study, the average pain intensity score for patients based on the 11-point visual analog scale dropped significantly from 8.8 +/1.4 to 1.8 +/2.1 within 24 hours of osteoplasty, said Anselmetti. "These patients experienced immediate and substantial pain relief. They did not require pain medication during the time of follow-up, and there were no clinically significant complications," said Anselmetti. Of 81 patients (59 women, 12 men), 64 (79 percent) were able to stop taking narcotic drugs for their pain, and 43 (53 percent) could stop taking other pain medication. In this study, pelvic, femur, sacrum, ribs, homerus, scapula, tibia, pubis and knee bones were treated.

In one case, Anselmetti recounted, a 79-year-old Roman Catholic nun had severe pain and was bedridden because of cancerous osteolytic lesions (thyroid cancer metastases) located deep in her pelvis -- previously treated unsuccessfully with chemotherapy and radiotherapy. She underwent osteoplasty and experienced significant relief of pain and was able to walk two hours after the procedure. "This is the Lazarus effect," said Anselmetti, referring to the term often used to connote an apparent restoration to life, with Lazarus being the subject of the miracle recounted in the New Testament in which Jesus raises him from the dead. The nun, like other patients, was able to be discharged from the hospital on the same day.

"I cannot emphasize enough how important it is to provide relief to patients who are dying from their cancers. In most cases we can provide pain relief, restore function for them to do daily activities and help them to stay ambulatory," said Anselmetti. He noted that osteoplasty provided effective pain regression for individuals with both painful bone metastases and benign lytic lesions that didn't respond to conventional analgesic treatment.

Bones are the third most common location where cancer cells spread and metastasize. Bone metastases occur when cancer cells gain access to the blood stream, reach the bone marrow, begin to multiply and then grow new blood vessels to obtain oxygen and food -- which in turn causes the cancer cells to grow more and spread. For the most part, the goal of treating bone tumors is not curative, but rather palliative by reducing pain, preventing additional bone destruction and improving function.

More information about osteoplasty, vertebroplasty, bone cancer and interventional radiology can be found online at www.SIRweb.org.

Abstract 36: "Percutaneous Osteoplasty Performed in Painful Extraspinal Osteolytic Lesions -- Personal Experience in 81 Patients Treated for Benign Diseases and Metastases," G. Anselmetti, G. Chiara, M. Liotti, M. Petracchini and D. Regge, Institute for Cancer Research and Treatment, Candiolo, Italy; and A. Manca, Institute for Cancer Research and Treatment, Candiolo, Italy, and the University of Sassari, Sassari, Italy, SIR 34th Annual Scientific Meeting March 7-12, 2009. This abstract can be found at www.SIRmeeting.org.

About the Society of Interventional Radiology

Interventional radiologists are physicians who specialize in minimally invasive, targeted treatments. They offer the most in-depth knowledge of the least invasive treatments available coupled with diagnostic and clinical experience across all specialties. They use X-ray, MRI and other imaging to advance a catheter in the body, usually in an artery, to treat at the source of the disease internally. As the inventors of angioplasty and the catheter-delivered stent, which were first used in the legs to treat peripheral arterial disease, interventional radiologists pioneered minimally invasive modern medicine. Today, interventional oncology is a growing specialty area of interventional radiology. Interventional radiologists can deliver treatments for cancer directly to the tumor without significant side effects or damage to nearby normal tissue.

Many conditions that once required surgery can be treated less invasively by interventional radiologists. Interventional radiology treatments offer less risk, less pain and less recovery time compared to open surgery. Visit www.SIRweb.org.

An estimated 5,300 people are attending the Society of Interventional Radiology's 34th Annual Scientific Meeting in San Diego.


'/>"/>
SOURCE Society of Interventional Radiology
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Oncolytics Biotech Inc. Announces Start of Patient Enrolment in Translational Clinical Trial Investigating REOLYSIN(R) in Patients with Metastatic Colorectal Cancer
2. Study Finds DOXIL(R) Combination Therapy Delays Disease Progression for Patients With Metastatic Breast Cancer
3. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
4. Bionovo Presents Positive Results from Phase 1B Trial of BZL101 for Metastatic Breast Cancer at the Society for Integrative Oncology
5. Bionovo Advances BZL101 to Phase 2 Clinical Trials After Positive Phase 1 Results for Metastatic Breast Cancer
6. CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
7. CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma
8. Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
9. Journal of Clinical Oncology Article Highlights CellSearch(TM) Circulating Tumor Cell Test in Treatment of Metastatic Colorectal Cancer
10. Rosetta Genomics and Collaborators Identify MicroRNAs That Can Accurately Discriminate Between Primary and Metastatic Tumors in the Brain
11. Results Published in the Journal Cancer Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... 10, 2016 CSI Specialty Group (CSI) expanded ... of the Specialty Pharmacy Podcast. A free, weekly show, ... providing real-world education, discussion and context amongst specialty pharmacy ... --> The Specialty Pharmacy Podcast, hosted ... Specialty Group Suzette DiMascio, CHE, CMCE, CPC, is available ...
(Date:2/10/2016)... Feb. 10, 2016 Immune Pharmaceuticals Inc. (NASDAQ: ... today that it has filed a patent application directed ... cancers. --> --> ... administration of Ceplene (histamine dihydrochloride) in combination with immune ... predicting the efficacy of Ceplene and IL-2 therapy in ...
(Date:2/10/2016)... , Feb. 10, 2016  The ALS Association, in ... the Grand Challenge to generate a biomarker to track TDP43 ... receive up to a $1 million investment. ... neurodegenerative disease that affects nerve cells in the brain and ... to initiate and control muscle movement, which often leads to ...
Breaking Medicine Technology:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... and Video Remote Interpreting (VRI) within Healthcare, recently partnered with Heart City ... interpreting (VRI). , For nearly 23 years, Heart City Health Center has provided ...
(Date:2/10/2016)... ... , ... 10 Best Water is excited to announce a new ... that topped the list as a result of their commitment to offering clients creative, ... Tibet 5100, a top notch water company that specializes in providing the public with ...
(Date:2/10/2016)... ... February 10, 2016 , ... United ... Nesbitt as the latest addition to its growing list of Partner Firms. ... the Southeast, from Orlando to Huntsville and in between. , Harnessing the experience ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... measure change in their patients. Research shows that the Goal Attainment Scale (GAS) ... therapists overcome this challenge and learn more about the Goal Attainment Scale, Education ...
(Date:2/10/2016)... ... 10, 2016 , ... IDEX Health & Science, LLC announces ... (PLS) columns combine the strength of traditional stainless steel with the chemical inertness ... while operating at ultra-high pressures of 20,000 psi. The higher operating pressures allow ...
Breaking Medicine News(10 mins):